Efficacy News and Research

RSS
Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

FDA grants Fast Track designations for IV and oral formulations of Tetraphase's eravacycline

FDA grants Fast Track designations for IV and oral formulations of Tetraphase's eravacycline

JPIAMR outlines steps to minimise antimicrobial resistance

JPIAMR outlines steps to minimise antimicrobial resistance

Sanaria receives 2014 Vaccine Industry Excellence Award for "Best Prophylactic Vaccine"

Sanaria receives 2014 Vaccine Industry Excellence Award for "Best Prophylactic Vaccine"

FDA allows CryoLife to begin PerClot clinical trial in the U.S.

FDA allows CryoLife to begin PerClot clinical trial in the U.S.

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

FDA approves ORALAIR sublingual allergy immunotherapy tablet

FDA approves ORALAIR sublingual allergy immunotherapy tablet

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Northwestern University awarded NIH grant to conduct phase III Parkinson's neuroprotective study

Northwestern University awarded NIH grant to conduct phase III Parkinson's neuroprotective study

Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma

Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma

Early strengthening activities can reduce cardiometabolic health risks in children

Early strengthening activities can reduce cardiometabolic health risks in children

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma gets approval to market Monarch eTNS System in Australia

DTI assessment indicates that mild hypothermia therapy may be beneficial for patients with diffuse axonal injury

DTI assessment indicates that mild hypothermia therapy may be beneficial for patients with diffuse axonal injury

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Bayer’s Adempas now available in the UK to treat patients with CTEPH

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Novel proteins may lead to new ways to combat venereal disease

Novel proteins may lead to new ways to combat venereal disease

Geographical variation in antipsychotic efficacy not ruled out

Geographical variation in antipsychotic efficacy not ruled out

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.